Kwon Hyuk Joon, Panagos Katherine, Alizadeh Madeline, Bell Mack, Bourmaf Mohammad, Zisman Erin, Paul Pinkle, Sibel Lauren, Wong Uni
Department of Internal Medicine, University of Maryland Medical Center, Baltimore, MD, United States.
Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, United States.
Front Med (Lausanne). 2022 Nov 15;9:1005121. doi: 10.3389/fmed.2022.1005121. eCollection 2022.
Despite the impact of the Coronavirus Disease 2019 (COVID-19) pandemic, vaccine hesitancy remains common in the general public and patients with Inflammatory Bowel Diseases (IBD). We sought to examine the reasons for vaccine hesitancy in patients with IBD. In this case-control study, we performed a retrospective chart review of 1,349 IBD patients and 215 non-IBD patients seen at University of Maryland Medical Center, a tertiary referral medical center, between March 2020 and October 2021. Data obtained included demographics, vaccination records, disease history, number of IBD-related surgeries, and IBD medications. 813/1,349 (60.3%) IBD patients received at least one dose of either the Pfizer/BioNTech, Moderna, or Johnson & Johnson vaccines. In a multivariate logistic regression, COVID vaccination was found to be positively associated with older age (value = 1.65e-5), female sex ( = 0.00194), Asian and White races ( = 0.02330, 0.00169), number of clinic visits ( = 1.11e-08), and biologic use ( = 7.82e-5). There was no association between vaccination and other types of vaccination nor with the use of other IBD medications. There was a negative association between vaccination status and the total number of IBD related surgeries ( = 0.02857). In non-IBD patients, only the number of clinic visits was positively associated with COVID-19 vaccination. Although the majority of IBD patients are immunosuppressed, COVID-19 vaccination rate was only 60.3%. Younger adults, males, African Americans, and those requiring IBD-related surgeries were less likely to receive COVID-19 vaccine. Healthcare providers need to recognize these potential risk factors for COVID-19 vaccine hesitancy.
尽管2019冠状病毒病（COVID-19）大流行产生了影响，但在普通公众和炎症性肠病（IBD）患者中，疫苗犹豫现象仍然普遍存在。我们试图探究IBD患者疫苗犹豫的原因。在这项病例对照研究中，我们对2020年3月至2021年10月期间在马里兰大学医学中心（一家三级转诊医疗中心）就诊的1349例IBD患者和215例非IBD患者进行了回顾性病历审查。获得的数据包括人口统计学信息、疫苗接种记录、疾病史、IBD相关手术次数以及IBD药物使用情况。1349例IBD患者中有813例（60.3%）至少接种了一剂辉瑞/生物科技、莫德纳或强生疫苗。在多因素逻辑回归分析中，发现COVID-19疫苗接种与年龄较大（值 = 1.65e - 5）、女性（ = 0.00194）、亚裔和白人种族（ = 0.02330，0.00169）、门诊就诊次数（ = 1.11e - 08）以及使用生物制剂（ = 7.82e - 5）呈正相关。疫苗接种与其他类型的疫苗接种以及其他IBD药物的使用之间没有关联。疫苗接种状态与IBD相关手术的总数之间存在负相关（ =
